TY - JOUR
T1 - Impact of sinus rhythm maintenance on major adverse cardiac and cerebrovascular events after catheter ablation of atrial fibrillation
T2 - insights from AF frontier ablation registry
AU - on behalf of the AF Ablation Frontier Registry
AU - Usuda, Keisuke
AU - Kato, Takeshi
AU - Tsuda, Toyonobu
AU - Tada, Hayato
AU - Niwa, Satoru
AU - Usui, Soichiro
AU - Sakata, Kenji
AU - Hayashi, Kenshi
AU - Furusho, Hiroshi
AU - Kawashiri, Masaaki
AU - Takamura, Masayuki
AU - Otsuka, Takayuki
AU - Suzuki, Shinya
AU - Hirata, Akio
AU - Murakami, Masato
AU - Takami, Mitsuru
AU - Kimura, Masaomi
AU - Fukaya, Hidehira
AU - Nakahara, Shiro
AU - Shimizu, Wataru
AU - Iwasaki, Yu ki
AU - Hayashi, Hiroshi
AU - Harada, Tomoo
AU - Nakajima, Ikutaro
AU - Okumura, Ken
AU - Koyama, Junjiroh
AU - Tokuda, Michifumi
AU - Yamane, Teiichi
AU - Momiyama, Yukihiko
AU - Tanimoto, Kojiro
AU - Soejima, Kyoko
AU - Nonoguchi, Noriko
AU - Ejima, Koichiro
AU - Hagiwara, Nobuhisa
AU - Harada, Masahide
AU - Sonoda, Kazumasa
AU - Inoue, Masaru
AU - Kumagai, Koji
AU - Hayashi, Hidemori
AU - Satomi, Kazuhiro
AU - Yazaki, Yoshinao
AU - Watari, Yuji
AU - Arai, Masaru
AU - Watanabe, Ryuta
AU - Yokoyama, Katsuaki
AU - Matsumoto, Naoya
AU - Nagashima, Koichi
AU - Okumura, Yasuo
N1 - Funding Information:
The following authors have potential conflicts of interest: T.K. received a research grant from Daiichi-Sankyo, and lecture fees from Bristol-Myers Squibb, Daiichi-Sankyo and Nippon Boehringer Ingelheim, and honoraria for writing promotional material for Bristol-Myers Squibb. S.S. received research funding from Daiichi-Sankyo and Mitsubishi-Tanabe. A.H. accepted remuneration from Nippon Boehringer Ingelheim, Bayer Healthcare, Bristol-Myers Squibb, Daiichi-Sankyo. M. Kimura accepted remuneration from Johnson & Johnson K.K., Medtronic Japan, Bayer Healthcare. H. Fukaya received lecture fees from Nippon Boehringer Ingelheim and Daiichi-Sankyo. S. Nakahara received lecture fees from Bayer Healthcare, Daiichi-Sankyo, Bristol-Meyers Squibb, Pfizer Japan, and Nippon Boehringer Ingelheim. W.S. received research funding from Bristol–Myers Squibb, Daiichi-Sankyo, and Nippon Boehringer Ingelheim, and patent royalties/licensing fees from Daiichi-Sankyo, Pfizer Japan, Bristol-Myers Squibb, Bayer Healthcare, and Nippon Boehringer Ingelheim. T.H. serves as a consultant to Medtronic Japan and has received lecture fees from Daiichi-Sankyo. I.N. received a scholarship from the Japanese Heart Rhythm Society and speaking honoraria from Medtronic Japan. K.O. received remuneration from Nippon Boehringer Ingelheim, Daiichi-Sankyo, Johnson & Johnson, and Medtronic Japan. M. Tokuda serves as a consultant to Medtronic Japan. T.Y. received lecture fees from Daiichi-Sankyo and Abbott Medical Japan. K.T. received lecture fees from Daiichi-Sankyo, Nippon Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer Japan, Bayer Healthcare. K. Soejima received research funding from Daiichi-Sankyo and Nippon Boehringer Ingelheim, and accepted remuneration from Medtronic Japan, Jonson & Jonson, and Abbott Medical Japan. N.H. accepted remuneration from Nippon Boehringer Ingelheim, Bristol-Myers Squibb, Bayer Healthcare, and research funding from Bayer Healthcare, Nippon Boehringer Ingelheim, Daiichi-Sankyo. M.H. received lecture fee from Nippon Boehringer Ingelheim, Daiichi-Sankyo, and Johnson & Johnson. K. Satomi and Y.Y. received research funding from BIOTRONIK Japan. N.M. received research funding from Daiichi-Sankyo. Y.O. received research funding from Bayer Healthcare, Daiichi-Sankyo, Bristol-Meyers Squibb, Nippon Boehringer Ingelheim, Pfizer Japan, TORAY, and Boston Scientific Japan and has accepted remuneration from Bayer Healthcare, Daiichi-Sankyo, and Bristol-Meyers Squibb. Other authors have no conflicts of interest.
Publisher Copyright:
© 2021, Springer Japan KK, part of Springer Nature.
PY - 2022/2
Y1 - 2022/2
N2 - The impact of catheter ablation for atrial fibrillation (AF) on cardiovascular events and mortality is controversial. We investigated the impact of sinus rhythm maintenance on major adverse cardiac and cerebrovascular events after AF ablation from a Japanese multicenter cohort of AF ablation. We investigated 3326 consecutive patients (25.8% female, mean age 63.3 ± 10.3 years) who underwent catheter ablation for AF from the atrial fibrillation registry to follow the long-term outcomes and use of anti coagulants after ablation (AF frontier ablation registry). The primary endpoint was a composite of stroke, transient ischemic attack, cardiovascular events, and all-cause death. During a mean follow-up of 24.0 months, 2339 (70.3%) patients were free from AF after catheter ablation, and the primary composite endpoint occurred in 144 (4.3%) patients. The AF nonrecurrence group had a significantly lower incidence of the primary endpoint (1.8 per 100 person-years) compared with the AF recurrence group (3.0 per 100 person-years, p = 0.003). The multivariate analysis revealed that freedom from AF (hazard ratio 0.61, 95% confidence interval 0.44–0.86, p = 0.005) was independently associated with the incidence of the composite event. In the multicenter cohort of AF ablation, sinus rhythm maintenance after catheter ablation was independently associated with lower rates of major adverse cardiac and cerebrovascular events.
AB - The impact of catheter ablation for atrial fibrillation (AF) on cardiovascular events and mortality is controversial. We investigated the impact of sinus rhythm maintenance on major adverse cardiac and cerebrovascular events after AF ablation from a Japanese multicenter cohort of AF ablation. We investigated 3326 consecutive patients (25.8% female, mean age 63.3 ± 10.3 years) who underwent catheter ablation for AF from the atrial fibrillation registry to follow the long-term outcomes and use of anti coagulants after ablation (AF frontier ablation registry). The primary endpoint was a composite of stroke, transient ischemic attack, cardiovascular events, and all-cause death. During a mean follow-up of 24.0 months, 2339 (70.3%) patients were free from AF after catheter ablation, and the primary composite endpoint occurred in 144 (4.3%) patients. The AF nonrecurrence group had a significantly lower incidence of the primary endpoint (1.8 per 100 person-years) compared with the AF recurrence group (3.0 per 100 person-years, p = 0.003). The multivariate analysis revealed that freedom from AF (hazard ratio 0.61, 95% confidence interval 0.44–0.86, p = 0.005) was independently associated with the incidence of the composite event. In the multicenter cohort of AF ablation, sinus rhythm maintenance after catheter ablation was independently associated with lower rates of major adverse cardiac and cerebrovascular events.
UR - http://www.scopus.com/inward/record.url?scp=85114909922&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114909922&partnerID=8YFLogxK
U2 - 10.1007/s00380-021-01929-5
DO - 10.1007/s00380-021-01929-5
M3 - Article
C2 - 34524497
AN - SCOPUS:85114909922
SN - 0910-8327
VL - 37
SP - 327
EP - 336
JO - Heart and Vessels
JF - Heart and Vessels
IS - 2
ER -